Cis-Diamminedichloroplatinum Ii
Adenosquamous Lung Carcinoma
Explore 13 assets in Adenosquamous Lung Carcinoma →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Barbara Ann Karmanos Cancer Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00005838CT.gov Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenosquamous Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Barbara Ann Karmanos Cancer Institute | P3 | BB · 70 |
| Carboplatin | NRG Oncology | P3 | BB |
| Gefitinib | National Cancer Institute (NCI) | P3 | BB |
| Shark Cartilage Extract | National Cancer Institute (NCI) | P3 | BB |
| Vinorelbine Ditartrate | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2/3 | B |
| Cetuximab | National Cancer Institute (NCI) | P2 | B |
| Docetaxel | Wake Forest University Health Sciences | P2 | B |
+14 more in the Adenosquamous Lung Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Adenosquamous Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-adenosquamous-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →